13F Holdings
中文EN

MLYS Mineralys Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1933414 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-115.9%
TTM EPS YoY-47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-68.5%
ROA-60.2%
ROIC (approx.)-80.9%
Asset turnover—

Leverage & solvency

Liabilities / assets20.1%
Debt / equity0.00x
Current ratio11.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.41x
Accruals ratio-35.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$22.67M$221.38M$24.36M$24.40M$31.45M$38.28M$37.88M$44.57M
SG&A expense$37.42M$24.66M$20.98M$13.88M$9.68M$8.47M$6.57M$7.20M
Operating income-$60.09M-$246.04M-$45.34M-$38.28M-$41.13M-$46.75M-$44.45M-$51.77M
Interest expense$3.19M———$0———
Income tax———$0————
Net income-$57.33M-$241.07M-$39.34M-$32.23M-$36.93M-$43.27M-$42.21M-$48.95M
EBITDA-$60.08M-$246.03M-$45.33M-$38.27M-$41.12M-$46.73M-$44.43M-$51.75M
EPS (basic)-0.64-2.85-0.47—-0.52-0.66-0.79—
EPS (diluted)-0.64-2.85-0.47—-0.52-0.66-0.79—
Weighted avg. shares (diluted)88.99M84.73M82.83M—70.59M65.45M53.16M—
Balance sheet
Cash & equivalents$101.27M$138.27M$112.78M$172.92M$217.60M$101.79M$165.01M$114.09M
Current assets$627.99M$665.80M$652.47M$661.39M$599.80M$335.27M$354.51M$205.35M
PP&E, net$21,000$27,000$32,000$38,000$7,000$22,000$38,000$53,000
Total assets$630.12M$667.85M$652.86M$661.81M$599.95M$335.72M$354.94M$205.90M
Current liabilities$53.08M$19.32M$14.72M$15.11M$23.52M$22.17M$13.39M$14.65M
Long-term debt$100,000$100,000——————
Total debt$100,000$100,000——————
Total liabilities$126.35M$116.94M$14.72M$15.11M$23.52M$22.17M$13.39M$14.65M
Shareholders' equity$503.77M$550.92M$638.14M$646.69M$576.43M$313.55M$341.56M$191.26M
Net debt-$101.17M-$138.17M——————
Shares outstanding88.53M88.35M82.45M81.54M78.97M65.73M64.88M49.82M
Cash flow statement
Operating cash flow-$43.10M-$32.56M-$39.47M-$37.89M-$28.87M-$30.17M-$45.49M-$66.84M
Capital expenditure———$15,000$0$0$0$0
Free cash flow———-$37.90M-$28.87M-$30.17M-$45.49M-$66.84M
Investing cash flow$4.70M-$185.22M-$44.94M-$103.49M-$150.51M-$42.88M-$92.88M$83.57M
Financing cash flow$1.40M$243.26M$24.27M$96.70M$295.19M$9.83M$189.28M$90,000
Depreciation & amortization$6,000$5,000$6,000$13,000$15,000$16,000$15,000$15,000
Stock-based compensation$7.88M$7.36M$6.55M$5.29M$5.84M$4.55M$3.65M$3.13M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.